Loading...
•
Mar 31, 2022
Celldex Q1 2022 Earnings Report
Reported financial results for the first quarter ended March 31, 2022 and provided a corporate update.
Key Takeaways
Celldex Therapeutics reported a net loss of $23.1 million, or ($0.49) per share, for the first quarter of 2022. Cash, cash equivalents and marketable securities as of March 31, 2022 were $380.5 million. The company believes that the cash, cash equivalents and marketable securities at March 31, 2022 are sufficient to meet estimated working capital requirements and fund planned operations through 2025.
Cash, cash equivalents and marketable securities as of March 31, 2022 were $380.5 million.
Total revenue was $0.2 million in the first quarter of 2022.
Research and development (R&D) expenses were $17.1 million in the first quarter of 2022.
Net loss was $23.1 million, or ($0.49) per share, for the first quarter of 2022.